Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10456134" target="_blank" >RIV/00064165:_____/22:10456134 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10456134

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=eEcG.QFRcw" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=eEcG.QFRcw</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2022.280660" target="_blank" >10.3324/haematol.2022.280660</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Popis výsledku v původním jazyce

Gain/amplification of 1q21, referred to as 1q21+ in this letter, is one of the most common chromosomal abnormalities in multiple myeloma (MM), being detected in approximately 40% of patients at diagnosis. The number of MM cells with 1q21+ and the number of copies of 1q21+ increases as the disease progresses. Furthermore, its negative impact on prognosis suggests that 1q21+ is involved in the pathophysiology of disease progression and resistance to MM treatment. The 1q21+ abnormality is defined as gain of 1q21 (gain[1q21], 3 copies) and amplification of 1q21 (amp[1q21], &gt;=4 copies). Co-existence of certain high-risk chromosomal abnormalities is common and further worsens the prognosis for patients with 1q21+. In the phase III studies ICARIA-MM and IKEMA, the addition of the anti-CD38 monoclonal antibody isatuximab (Isa) to the backbone of pomalidomide-dexamethasone (Pd) or carfilzomib-dexamethasone (Kd), respectively, improved progression-free survival (PFS) among patients with relapsed/refractory MM, and subgroup analyses suggested benefit among patients with 1q21+. The current analyses examine four subgroups of patients from ICARIA-MM and IKEMA: 1q21+ (&gt;=3 copies with or without high-risk chromosomal abnormalities), isolated 1q21+ (&gt;=3 copies without high-risk chromosomal abnormalities), gain(1q21) (3 copies with or without high-risk chromosomal abnormalities), and amp(1q21) (&gt;=4 copies with or without high-risk chromosomal abnormalities). The analyses show a clear benefit of Isa-based combinations in 1q21+ disease.

Název v anglickém jazyce

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Popis výsledku anglicky

Gain/amplification of 1q21, referred to as 1q21+ in this letter, is one of the most common chromosomal abnormalities in multiple myeloma (MM), being detected in approximately 40% of patients at diagnosis. The number of MM cells with 1q21+ and the number of copies of 1q21+ increases as the disease progresses. Furthermore, its negative impact on prognosis suggests that 1q21+ is involved in the pathophysiology of disease progression and resistance to MM treatment. The 1q21+ abnormality is defined as gain of 1q21 (gain[1q21], 3 copies) and amplification of 1q21 (amp[1q21], &gt;=4 copies). Co-existence of certain high-risk chromosomal abnormalities is common and further worsens the prognosis for patients with 1q21+. In the phase III studies ICARIA-MM and IKEMA, the addition of the anti-CD38 monoclonal antibody isatuximab (Isa) to the backbone of pomalidomide-dexamethasone (Pd) or carfilzomib-dexamethasone (Kd), respectively, improved progression-free survival (PFS) among patients with relapsed/refractory MM, and subgroup analyses suggested benefit among patients with 1q21+. The current analyses examine four subgroups of patients from ICARIA-MM and IKEMA: 1q21+ (&gt;=3 copies with or without high-risk chromosomal abnormalities), isolated 1q21+ (&gt;=3 copies without high-risk chromosomal abnormalities), gain(1q21) (3 copies with or without high-risk chromosomal abnormalities), and amp(1q21) (&gt;=4 copies with or without high-risk chromosomal abnormalities). The analyses show a clear benefit of Isa-based combinations in 1q21+ disease.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

1592-8721

Svazek periodika

107

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

7

Strana od-do

2485-2491

Kód UT WoS článku

000870533100022

EID výsledku v databázi Scopus

2-s2.0-85139536296